

KNOW YOUR VACCINES

source: Department of Health

	Pfizer BioNTech	Oxford AstraZeneca	Sinovac CoronaVac	Gamaleya Sputnik V	Janssen	Bharat Biotech	Moderna	Nova-vax
Technology Platform	mRNA	Viral Vector (non-replicating)	Inactivated Virus	Viral Vector (non-replicating)	Viral Vector (non-replicating)	Inactivated Virus	mRNA	Protein Subunit
Philippines FDA EUA Approval [A]	January 14, 2021	January 28, 2021	February 22, 2021	March 19, 2021	April 19, 2021	April 19, 2021	May 5, 2021	
Dose and Frequency	2 doses, 21 days apart [A]	2 doses, 4-12 weeks apart [A]	2 doses, 28 days apart [A]	2 doses, 3 weeks apart [A]	1 dose [A]	2 doses, 14 days apart [A]	2 doses, 28 days apart [B]	2 doses, 21 days apart [C]
Storage Requirements	-80 to 60°C [A]	2 to 8°C [A]	2 to 8°C [A]	-18°C and below (frozen solution) [A]	2 to 8°C (3 months) [A]	2 to 8°C [A]	-25 to -15°C 2 to 8°C (30 days) [E]	2 to 8°C [H]
Vaccine Efficacy Based on Phase III Clinical Trial (CT)	95% against symptomatic COVID-19 [A] [B]	70.4% against symptomatic COVID-19 [B] 100% against Severe COVID-19 [B]	65-91% (based on Brazil, Indonesia, and Turkey Trials) [A]	91.6% against symptomatic COVID-19 [B] 100% against moderate or severe cases [B]	66.1-66.9% against confirmed moderate to severe/critical COVID-19 ~77-85% against severe COVID-19 [J]	80.6% against PCR-confirmed symptomatic COVID-19 [E]	94.1% against symptomatic COVID-19 [B] 100% against severe COVID-19 [B]	Awaiting official Phase III Interim Journal Publication
Common Adverse Events Reported Observed in Phase III CT	<ul style="list-style-type: none"> Short-term, mild-to-moderate pain at the injection site Fatigue, headache 	<ul style="list-style-type: none"> Injection site pain and tenderness Fatigue, headache, feverishness, myalgia [B] 	<ul style="list-style-type: none"> Local lymphadenopathy at the injection site Allergic reaction that may be caused by any component of the vaccine (hives, allergic rashes and purpura, anaphylactic shock) Convulsion (with or without fever) [I] 	<ul style="list-style-type: none"> Pain on injection site, hyperthermia swelling [B] Headache, asthenia, Muscle/joint pain malaise, sore throat diarrhea, rhinorrhea, Loss of appetite, pain in the oropharynx, Nasal congestion, colds, sneezing, cough [B] 	<ul style="list-style-type: none"> Injection site pain, redness, swelling Tiredness, headache, muscle pain, chills, fever, nausea [G] 	<ul style="list-style-type: none"> Headache Fatigue Fever Body ache Abdominal pain Nausea Vomiting [E] 	<ul style="list-style-type: none"> Pain/erythema/swelling on injection site axillary lymphadenopathy [B] Fever, headache, fatigue, myalgia, arthralgia, nausea, vomiting, chills [B] 	Awaiting official Phase III Interim Journal Publication

References: [A] FDA Philippines EUA Approval [B] Publication in Journals for Phase III Interim Results [C] WHO Landscape and Tracker of COVID-19 Candidate Vaccines [D] WHO Interim recommendations for EUL [E] Submission to FDA EUA Application [F] Clinicaltrials.gov [G] Center for Disease Control and Prevention [H] Publication in Journals for Phase I and/or Phase II CT results [I] FDA Published Product Information

Prepared by:



GENDER AND DEVELOPMENT OFFICE